Literature DB >> 23808395

Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079.

Alba Jimenez-Pacheco1, Guillaume Mesuret, Amaya Sanz-Rodriguez, Katsuhiro Tanaka, Claire Mooney, Ronan Conroy, Maria Teresa Miras-Portugal, Miguel Diaz-Hernandez, David C Henshall, Tobias Engel.   

Abstract

PURPOSE: ATP is an essential transmitter/cotransmitter in neuron function and pathophysiology and has recently emerged as a potential contributor to prolonged seizures (status epilepticus) through the activation of the purinergic ionotropic P2X7 receptor (P2X7R). Increased P2X7R expression has been reported in the hippocampus, and P2X7R antagonists reduced seizure-induced damage to this brain region. However, status epilepticus also produces damage to the neocortex. The present study was designed to characterize P2X7R in the neocortex and assess effects of P2X7R antagonists on cortical injury after status epilepticus.
METHODS: Status epilepticus was induced in mice by intraamygdala microinjection of kainic acid. Specific P2X7R inhibitors were administered into the ventricle before seizure induction, and cortical electroencephalography and behavior was recorded to assess seizure severity. P2X7R expression was examined in neocortex up to 24 h after status epilepticus, in epileptic mice, and in resected neocortex from patients with pharmacoresistent temporal lobe epilepsy (TLE). In addition, the induction of P2X7R after status epilepticus was investigated using transgenic P2X7R reporter mice, which express enhanced green fluorescent protein under the control of the p2x7r promoter. KEY
FINDINGS: Status epilepticus resulted in increased P2X7R protein levels in the neocortex of mice. Neocortical P2X7 receptor levels were also elevated in mice that developed epilepsy after status epilepticus and in resected neocortex from patients with pharmacoresistent TLE. Immunohistochemistry determined that neurons were the major cell population transcribing the P2X7R in the neocortex within the first 8 h after status epilepticus, whereas in epileptic mice, P2X7R up-regulation occurred in microglia as well as in neurons. Pretreatment of mice with the specific P2X7R inhibitor A-438079 reduced electrographic and clinical seizure severity during status epilepticus and reduced seizure-induced neuronal death in the neocortex. SIGNIFICANCE: Our findings identify neurons in the neocortex as an important site of P2X7R up-regulation after status epilepticus and in epilepsy, and provide support for the possible use of P2X7R antagonists for the treatment of status epilepticus and prevention of seizure-induced brain damage. Wiley Periodicals, Inc.
© 2013 International League Against Epilepsy.

Entities:  

Keywords:  ATP; Cortex; Neuroprotection; P2X7 receptor; Status epilepticus

Mesh:

Substances:

Year:  2013        PMID: 23808395     DOI: 10.1111/epi.12257

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  53 in total

1.  Silencing of P2X7R by RNA interference in the hippocampus can attenuate morphological and behavioral impact of pilocarpine-induced epilepsy.

Authors:  Rebeca Padrão Amorim; Michelle Gasparetti Leão Araújo; Jorge Valero; Iscia Lopes-Cendes; Vinicius Davila Bitencourt Pascoal; João Oliveira Malva; Maria José da Silva Fernandes
Journal:  Purinergic Signal       Date:  2017-07-13       Impact factor: 3.765

2.  Persistent Protection Against Pathology and Paroxysms by P2X7R Antagonism.

Authors:  Catherine A Christian
Journal:  Epilepsy Curr       Date:  2018 Jan-Feb       Impact factor: 7.500

3.  Functional P2X7 Receptors in the Auditory Nerve of Hearing Rodents Localize Exclusively to Peripheral Glia.

Authors:  Silvia Prades; Gregory Heard; Jonathan E Gale; Tobias Engel; Robin Kopp; Annette Nicke; Katie E Smith; Daniel J Jagger
Journal:  J Neurosci       Date:  2021-02-09       Impact factor: 6.167

4.  Inhibition of P2X7 receptors improves outcomes after traumatic brain injury in rats.

Authors:  Xiaofeng Liu; Zhengqing Zhao; Ruihua Ji; Jiao Zhu; Qian-Qian Sui; Gillian E Knight; Geoffrey Burnstock; Cheng He; Hongbin Yuan; Zhenghua Xiang
Journal:  Purinergic Signal       Date:  2017-08-19       Impact factor: 3.765

5.  Macrophage-Inducible C-Type Lectin/Spleen Tyrosine Kinase Signaling Pathway Contributes to Neuroinflammation After Subarachnoid Hemorrhage in Rats.

Authors:  Yue He; Liang Xu; Bo Li; Zhen-Ni Guo; Qin Hu; Zongduo Guo; Junjia Tang; Yujie Chen; Yang Zhang; Jiping Tang; John H Zhang
Journal:  Stroke       Date:  2015-07-02       Impact factor: 7.914

Review 6.  Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.

Authors:  Robin Ortiz; Henning Ulrich; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-11-07       Impact factor: 5.067

7.  Inhibition of P2X7 Receptor Ameliorates Nuclear Factor-Kappa B Mediated Neuroinflammation Induced by Status Epilepticus in Rat Hippocampus.

Authors:  Cheng Huang; Xiao-Sa Chi; Rui Li; Xin Hu; Hai-Xia Xu; Jin-Mei Li; Dong Zhou
Journal:  J Mol Neurosci       Date:  2017-08-30       Impact factor: 3.444

8.  Adenosine A2A receptor and ecto-5'-nucleotidase/CD73 are upregulated in hippocampal astrocytes of human patients with mesial temporal lobe epilepsy (MTLE).

Authors:  Aurora R Barros-Barbosa; Fátima Ferreirinha; Ângela Oliveira; Marina Mendes; M Graça Lobo; Agostinho Santos; Rui Rangel; Julie Pelletier; Jean Sévigny; J Miguel Cordeiro; Paulo Correia-de-Sá
Journal:  Purinergic Signal       Date:  2016-09-20       Impact factor: 3.765

Review 9.  Microglia-Neuron Communication in Epilepsy.

Authors:  Ukpong B Eyo; Madhuvika Murugan; Long-Jun Wu
Journal:  Glia       Date:  2016-05-18       Impact factor: 7.452

10.  Liver kinase B1/AMP-activated protein kinase-mediated regulation by gentiopicroside ameliorates P2X7 receptor-dependent alcoholic hepatosteatosis.

Authors:  Xia Li; Yu Zhang; Quan Jin; Kai-Li Xia; Min Jiang; Ben-Wen Cui; Yan-Ling Wu; Shun-Zong Song; Li-Hua Lian; Ji-Xing Nan
Journal:  Br J Pharmacol       Date:  2018-03-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.